Supplemental Table 4. Performance of methods of reporting ACR and DAS28 criteria based on sustainability of response according to their discriminatory capacity, and their ability to reflect structural damage inhibition or patient satisfaction

ACR20 achieved for: / ≥1
visits / ≥2 visits* / ≥3 visits* / ≥4 visits* / ≥5 visits* / ≥6 visits*
Overall success / n/N
(%) / 502/636
(78.93) / 418/636
(65.72) / 333/636
(52.36) / 254/636
(39.94) / 199/636
(31.29) / 113/636
(17.77)
NNS† / n / 64 / 63 / 67 / 60 / 72 / 98
Structural damage at Year 1‡ / LR+ / 1.11 / 1.16 / 1.31 / 1.45 / 1.41 / 1.45
(95% CI) / 1.01, 1.22 / 1.02, 1.33 / 1.10, 1.55 / 1.17, 1.80 / 1.07, 1.85 / 0.96, 2.18
Patient satisfaction at Month 6§ / LR+ / 1.94 / 2.72 / 4.10 / 6.38 / 9.09 / 13.01
(95% CI) / 1.58, 2.37 / 2.03, 3.65 / 2.66, 6.31 / 3.38, 12.04 / 3.83, 21.60 / 3.26, 51.92
ACR70 achieved for: / ≥1
visits / ≥2 visits* / ≥3 visits* / ≥4 visits* / ≥5 visits* / ≥6 visits*
Overall success / n/N
(%) / 154/636
(24.21) / 80/636
(12.58) / 49/636
(7.70) / 30/636
(4.72) / 15/636
(2.36) / 5/636
(0.79)
NNS† / n / 99 / 110 / 204 / 273 / 723 / NA
Structural damage at Year 1‡ / LR+ / 1.23 / 1.18 / 2.02 / 1.92 / 2.64 / 3.53
(95% CI) / 0.87, 1.75 / 0.69, 2.01 / 1.11, 3.69 / 0.88, 4.19 / 0.92, 7.57 / 0.60, 20.82
Patient satisfaction at Month 6§ / LR+ / 8.79 / Infinite / Infinite / Infinite / Infinite / Infinite
(95% CI) / 3.32, 23.25 / NA / NA / NA / NA / NA
MDAS achieved for: / ≥1
visits / ≥2 visits* / ≥3 visits* / ≥4 visits* / ≥5 visits* / ≥6 visits*
Overall success / n/N
(%) / 523/636
(82.23) / 453/636
(71.23) / 387/636
(60.85) / 324/636
(50.94) / 261/636
(41.04) / 182/636
(28.62)
NNS† / n / 92 / 53 / 51 / 54 / 53 / 85
Structural damage at Year 1‡ / LR+ / 1.07 / 1.08 / 1.17 / 1.21 / 1.35 / 1.48
(95% CI) / 0.98, 1.17 / 0.95, 1.22 / 1.00, 1.36 / 1.01, 1.46 / 1.09, 1.68 / 1.11, 1.97
Patient satisfaction at Month 6§ / LR+ / 1.46 / 1.97 / 2.28 / 2.68 / 2.82 / 2.61
(95% CI) / 1.26, 1.70 / 1.57, 2.46 / 1.72, 3.01 / 1.89, 3.79 / 1.87, 4.26 / 1.60, 4.26
Remission achieved for: / ≥1
visits / ≥2 visits* / ≥3 visits* / ≥4 visits* / ≥5 visits* / ≥6 visits*
Overall success / n/N
(%) / 118/636
(18.55) / 53/636
(8.33) / 28/636
(4.40) / 19/636
(2.99) / 10/636
(1.57) / 4/636
(0.63)
NNS† / n / 114 / 145 / 242 / 400 / 1545 / NA
Structural damage at Year 1‡ / LR+ / 1.72 / 3.41 / 2.80 / 2.20 / 2.27 / 1.76
(95% CI) / 1.19, 2.49 / 2.03, 5.73 / 1.29, 6.10 / 0.79, 6.11 / 0.60, 8.61 / 0.19, 16.77
Patient satisfaction at Month 6§ / LR+ / 8.98 / Infinite / Infinite / Infinite / Infinite / Infinite
(95% CI) / 2.9, 27.8 / NA / NA / NA / NA / NA

*Consecutive visits: equal weighting was applied; The total number of patients for each analysis was: †n=638; ‡n=610; §n=632; Abatacept and placebo treatment groups were pooled for radiographic progression and patient satisfaction, and unpooled for NNS; NNS=Number of patients needed to study; LR+=positive likelihood ratio; CI=confidence interval; ACR=American College of Rheumatology; MDAS=DAS28<5.1; LDAS=DAS28(CRP) ≤3.2; remission=DAS28(CRP)<2.6.

1